Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Myeloproliferative Disorders 1Leukemia, Myeloid 1Leukemia 1

Interventions

Cyclophosphamide 15fludarabine phosphate 12Filgrastim 10Peripheral Blood Stem Cell Transplantation 9ruxolitinib 8Decitabine 8fludarabine 7Tacrolimus 7Etoposide 7Melphalan 6Cytarabine 6Azacitidine 6Vorinostat 5Mycophenolic Acid 5Ipilimumab 5venetoclax 4Specimen Handling 4Sirolimus 4Idarubicin 4Granulocyte Colony-Stimulating Factor 4ivosidenib 3fedratinib 3aldesleukin 3Whole-Body Irradiation 3Rituximab 3Radiotherapy 3Nivolumab 3Methylprednisolone 3Imatinib Mesylate 3Doxorubicin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Myeloproliferative Disorders × zileuton × Clear all
NCT01130688 2015-05-27

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

University of Massachusetts, Worcester

Phase 1 Terminated
2 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡